40th FDA Boot Camp

March 22-23, 2023

Virtual

American Conference Institute (ACI)

Finnegan partner Li Feng will join the panel discussion “PART 2: Hatch-Waxman and BPCIA Fundamentals: Understanding Follow-On Products and the Rules for Generic Entry” at the American Conference Institute’s (ACI) virtual FDA Boot Camp. For more information, or to register, please see ACI’s website.

Tags

Biologics Price Competition and Innovation Act (BPCIA), Food and Drug Administration (FDA)

Related Practices

Global IP Enforcement, Litigation, and Trials

Branded Hatch-Waxman (ANDA) Litigation and Trials

Related Industries

Related Offices

Related Professionals

Li Feng, Ph.D.: Partner; Washington, DC; +1 202 408 4382; Email

Related Insights

Articles

California Brings First CCPA and Delete Act Enforcement Action Against Data Broker

September 4, 2026

Articles

Beyond Hikma: Patent Prosecution Strategies for Anticipating Skinny-Label Generics in Pharmaceutical Patent Portfolios

September 2026

Articles

This Article Was Written Entirely by AI — Welcome to Synthetic Patent Litigation

July/August 2026

At the PTAB Blog

New Informative Decision Applies the USPTO’s U.S. Manufacturing and Small Business Use of AIA Proceedings Memo

June 18, 2026

Articles

The Interplay of Patent Term Extension (PTE) and Reissue: Merck v. Aurobindo and Its Implications, Part I

April 7, 2026

Articles

The Interplay of Patent Term Extension (PTE) and Reissue: Merck v. Aurobindo and Its Implications, Part II

April 7, 2026

Articles

Recent Developments in Video Privacy Protection Act Litigation

April 3, 2026

At the PTAB Blog

Rinsed at the PTAB: Director Pulls the Plug on a Late‑Stage IPR After ITC Validity Findings

March 5, 2026

Articles

Skinny labels, larger risks: Supreme Court considers induced infringement standards in Hikma v. Amarin

Skinny Labels, Larger Risks: Supreme Court Considers Induced Infringement Standards in Hikma v. Amarin

March 3, 2026